{
  "report_rows": [
    {
      "kpi": "Operating EPS",
      "prediction": "BEAT",
      "answer": "pred ~$10.35 vs. cons $10.10",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Global DUPIXENT sales",
      "prediction": "IN-LINE",
      "answer": "pred ~$5.40B vs. cons $5.367B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Global EYLEA sales",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.65B vs. cons $1.664B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "GAAP gross margin (FY26)",
      "prediction": "UNCHANGED",
      "answer": "guide ~77%-78% vs. company baseline 77%-78%; FY consensus UNVERIFIED",
      "confidence": "LOW"
    },
    {
      "kpi": "Sanofi profit-share step-up (Q3'26)",
      "prediction": "BETTER",
      "answer": "confirm end-Q2 repayment / full Q3 profit share; numeric consensus UNVERIFIED",
      "confidence": "LOW"
    },
    {
      "kpi": "EYLEA HD / legacy EYLEA demand (Q3'26)",
      "prediction": "UNCHANGED",
      "answer": "HD growth maintained, legacy erosion/pricing pressure persists; numeric consensus UNVERIFIED",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -2.5,
  "day1_confidence": "LOW",
  "day5_residual_pct": -4.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 C archetype and no new forward revenue catalyst",
  "day5_confidence": "LOW"
}